ALPMF - Anchiano Therapeutics Files For $35 Million U.S. IPO
Quick Take
Anchiano Therapeutics (ANCN) intends to raise $35 million from the sale of ADSs in a U.S IPO, per an F-1 registration statement.
The company is pursuing regulatory approvals for its drug treatment pipeline for various cancers.
ANCN has generated promising efficacy trial results for its treatment for NMIBC (bladder cancer).
I’ll provide an update when we learn more about the IPO from management.
Company & Technology
Israel-based Anchiano was founded in 2004 to develop treatments for patients with bladder cancer, pancreatic cancer, and ovarian cancer.
Management is headed by CEO